European Switch Progresses, But Stronger Incentives Needed For OTCs
This article was originally published in The Tan Sheet
Executive Summary
Europe needs to provide more incentives for consumer firms, otherwise the OTC industry will "make commercial decisions" that could reduce their presence in the area, suggested Manfred Scheske, Glaxo-SmithKline's Consumer Healthcare Europe president and VP of the Association of the European Self-Medication Industry, speaking at that organization's meeting in London Jan. 20
You may also be interested in...
GSK Consumer Vet Scheske Sees OTC Potential In Biotech PepTcell's Portfolio
PepTcell is in the late stages of developing a potential blockbuster cough suppressant, says Manfred Scheske, head of the U.K. biotech's consumer business
EU Centralized Switch Process Needs Longer Exclusivity, More Trust - Execs
Limited data protection and a lack of trust between industry and regulators are dampening enthusiasm for the European Union's centralized switch process, according to industry leaders
EU-Wide OTC Approvals Highlight The Drawbacks Of National Processes
National switches comprise the majority of OTC approvals in Europe, and likely will until the European Union opens restrictions on which drugs can use its nascent centralized switch process